An interventional study of wholegrain and refined wheat in Obesity, sponsored by University of Copenhagen. Completed at 1 site in Denmark. Open to female participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-03-26.
Sponsored by University of Copenhagen · Not applicable, Interventional, and Treatment
The aim of this study is to investigate the potential beneficial effect of wholegrain on body weight and composition as well as cardiovascular risk in overweight women.
Objective: To study the effect of the 'wholegrain concept', i.e. high intake of wheat wholegrain (WW) vs. refined wheat (RW) grain products on body weight and composition.
Design: In this open-labeled randomized trial, 72 postmenopausal women with metabolic syndrome features were prescribed a mild calorie-restricted diet with a deficit of \~1,250kJ/d. Following 2 weeks run-in period on RW products, they were randomized to 12 weeks intervention with RW or WW products providing 2,000kJ/d.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 85 is close to the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →University of Copenhagen is the lead sponsor of 450 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
wholegrain wheat
Other: wholegrain
refined wheat
Other: refined wheat
wholegrain wheat vs. refined wheat products
refined wheat products
Body weight and composition
Time frame: 0, 6 and 12 wks
Cardiovascular risk markers
Time frame: 0, 6 and 12 wks
Fecal parameters
Time frame: 0 and 12 wks
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Copenhagen